Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPRC5A siRNA
- Development stage
- Preclinical
- Lead developer
- Mayo Clinic
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- In Vitro
01
Overview
GPRC5A siRNA is a small interfering RNA (siRNA) designed to silence the expression of the G-protein coupled receptor class C group 5 member A (GPRC5A), an orphan retinoic acid-induced GPCR. In the context of respiratory research, GPRC5A siRNA is utilized as a laboratory tool to investigate the physiological role of GPRC5A in human airway smooth muscle (ASM) cells. Studies have demonstrated that knockdown of GPRC5A using siRNA leads to increased calcium responses to bronchoconstrictor agonists like histamine, particularly in asthmatic ASM cells. This suggests that GPRC5A normally functions to blunt these responses, identifying it as a potential therapeutic target for asthma and other airway diseases characterized by hyperresponsiveness.
- Other names
- GPRC5A small interfering RNAGPRC-5A small interfering RNAGPRC 5A small interfering RNARAIG1 siRNARAIG-1 siRNARAIG 1 siRNA
02
Targets
GPRC5A (G protein-coupled receptor class C group 5 member A)
Beyond the preview
Go deeper on GPRC5A siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPRC5A siRNA.